Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease

Hassan Kahal, G. Abouda, A. S. Rigby, A. M. Coady, E. S. Kilpatrick, Stephen Atkin

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Introduction: Nonalcoholic fatty liver disease (NAFLD) has been linked to polycystic ovary syndrome (PCOS) and carries an increased risk of liver cirrhosis. Procollagen type 3 amino-terminal peptide (PIIINP) is an independent predictor of liver cirrhosis. Objective: To assess whether 6-month treatment with GLP-1 analogue, liraglutide, improves markers of liver fibrosis. Design: A case-control study comparing women with PCOS to age- and weight-matched controls. PCOS was diagnosed according to the Rotterdam criteria. All participants underwent liver function tests and liver ultrasound scan to assess for fatty infiltration. Serum marker for liver fibrosis, PIIINP, was measured at baseline and after 6-month treatment with liraglutide 1.8 mg od. Results: Nineteen women with PCOS and 17 controls were recruited, age 32.8 ± 7.2 vs 33.5 ± 6.7 years and weight 100.9 ± 16.7 vs 99.3 ± 14.7 kg, respectively. At baseline, the PCOS group had higher testosterone 1.2 ± 0.3 vs 0.9 ± 0.3 nM (P = 0.01), HOMA-IR 5.1 ± 2.6 vs 3.5 ± 1.3 (P = 0.03), AST 22.4 ± 5.2 vs 18.8 ± 3.4 u/l (P = 0.04), PIIINP 4.4 ± 0.8 vs 3.5 ± 0.8 ug/ml (P = 0.01) and NAFLD seven (35%) vs none (P = 0.005), respectively. Twenty-five (69%) participants completed the study (13 PCOS, 12 controls). Following treatment, weight was reduced by 3.0 ± 4.2 kg (P = 0.01) and 3.8 ± 3.4 kg (P = 0.001), respectively. Similarly, HOMA-IR, hsCRP, triglycerides and urinary isoprostane significantly reduced in both groups. PIIINP significantly reduced the in PCOS group 4.4 ± 0.8 vs 3.7 ± 0.9 ug/ml (P < 0.01), but not in controls 3.5 ± 0.8 vs 3.2 ± 0.7 ug/ml (P = 0. 08). Conclusions: Treatment with liraglutide, and/or associated weight loss, significantly reduced PIIINP levels in obese women with PCOS. This may be an additional beneficial factor when considering the use of liraglutide in women with PCOS, obesity and NAFLD.

Original languageEnglish
Pages (from-to)523-528
Number of pages6
JournalClinical Endocrinology
Volume81
Issue number4
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Glucagon-Like Peptide 1
Polycystic Ovary Syndrome
Liver Cirrhosis
Weights and Measures
Isoprostanes
Non-alcoholic Fatty Liver Disease
Liraglutide
Collagen Type III
Liver Function Tests
Therapeutics
Testosterone
Case-Control Studies
Weight Loss
Triglycerides
Obesity
Biomarkers
procollagen Type III-N-terminal peptide
Peptides
Liver

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. / Kahal, Hassan; Abouda, G.; Rigby, A. S.; Coady, A. M.; Kilpatrick, E. S.; Atkin, Stephen.

In: Clinical Endocrinology, Vol. 81, No. 4, 2014, p. 523-528.

Research output: Contribution to journalArticle

@article{4d96d2c9c835419681857da144a372b4,
title = "Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease",
abstract = "Introduction: Nonalcoholic fatty liver disease (NAFLD) has been linked to polycystic ovary syndrome (PCOS) and carries an increased risk of liver cirrhosis. Procollagen type 3 amino-terminal peptide (PIIINP) is an independent predictor of liver cirrhosis. Objective: To assess whether 6-month treatment with GLP-1 analogue, liraglutide, improves markers of liver fibrosis. Design: A case-control study comparing women with PCOS to age- and weight-matched controls. PCOS was diagnosed according to the Rotterdam criteria. All participants underwent liver function tests and liver ultrasound scan to assess for fatty infiltration. Serum marker for liver fibrosis, PIIINP, was measured at baseline and after 6-month treatment with liraglutide 1.8 mg od. Results: Nineteen women with PCOS and 17 controls were recruited, age 32.8 ± 7.2 vs 33.5 ± 6.7 years and weight 100.9 ± 16.7 vs 99.3 ± 14.7 kg, respectively. At baseline, the PCOS group had higher testosterone 1.2 ± 0.3 vs 0.9 ± 0.3 nM (P = 0.01), HOMA-IR 5.1 ± 2.6 vs 3.5 ± 1.3 (P = 0.03), AST 22.4 ± 5.2 vs 18.8 ± 3.4 u/l (P = 0.04), PIIINP 4.4 ± 0.8 vs 3.5 ± 0.8 ug/ml (P = 0.01) and NAFLD seven (35{\%}) vs none (P = 0.005), respectively. Twenty-five (69{\%}) participants completed the study (13 PCOS, 12 controls). Following treatment, weight was reduced by 3.0 ± 4.2 kg (P = 0.01) and 3.8 ± 3.4 kg (P = 0.001), respectively. Similarly, HOMA-IR, hsCRP, triglycerides and urinary isoprostane significantly reduced in both groups. PIIINP significantly reduced the in PCOS group 4.4 ± 0.8 vs 3.7 ± 0.9 ug/ml (P < 0.01), but not in controls 3.5 ± 0.8 vs 3.2 ± 0.7 ug/ml (P = 0. 08). Conclusions: Treatment with liraglutide, and/or associated weight loss, significantly reduced PIIINP levels in obese women with PCOS. This may be an additional beneficial factor when considering the use of liraglutide in women with PCOS, obesity and NAFLD.",
author = "Hassan Kahal and G. Abouda and Rigby, {A. S.} and Coady, {A. M.} and Kilpatrick, {E. S.} and Stephen Atkin",
year = "2014",
doi = "10.1111/cen.12369",
language = "English",
volume = "81",
pages = "523--528",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease

AU - Kahal, Hassan

AU - Abouda, G.

AU - Rigby, A. S.

AU - Coady, A. M.

AU - Kilpatrick, E. S.

AU - Atkin, Stephen

PY - 2014

Y1 - 2014

N2 - Introduction: Nonalcoholic fatty liver disease (NAFLD) has been linked to polycystic ovary syndrome (PCOS) and carries an increased risk of liver cirrhosis. Procollagen type 3 amino-terminal peptide (PIIINP) is an independent predictor of liver cirrhosis. Objective: To assess whether 6-month treatment with GLP-1 analogue, liraglutide, improves markers of liver fibrosis. Design: A case-control study comparing women with PCOS to age- and weight-matched controls. PCOS was diagnosed according to the Rotterdam criteria. All participants underwent liver function tests and liver ultrasound scan to assess for fatty infiltration. Serum marker for liver fibrosis, PIIINP, was measured at baseline and after 6-month treatment with liraglutide 1.8 mg od. Results: Nineteen women with PCOS and 17 controls were recruited, age 32.8 ± 7.2 vs 33.5 ± 6.7 years and weight 100.9 ± 16.7 vs 99.3 ± 14.7 kg, respectively. At baseline, the PCOS group had higher testosterone 1.2 ± 0.3 vs 0.9 ± 0.3 nM (P = 0.01), HOMA-IR 5.1 ± 2.6 vs 3.5 ± 1.3 (P = 0.03), AST 22.4 ± 5.2 vs 18.8 ± 3.4 u/l (P = 0.04), PIIINP 4.4 ± 0.8 vs 3.5 ± 0.8 ug/ml (P = 0.01) and NAFLD seven (35%) vs none (P = 0.005), respectively. Twenty-five (69%) participants completed the study (13 PCOS, 12 controls). Following treatment, weight was reduced by 3.0 ± 4.2 kg (P = 0.01) and 3.8 ± 3.4 kg (P = 0.001), respectively. Similarly, HOMA-IR, hsCRP, triglycerides and urinary isoprostane significantly reduced in both groups. PIIINP significantly reduced the in PCOS group 4.4 ± 0.8 vs 3.7 ± 0.9 ug/ml (P < 0.01), but not in controls 3.5 ± 0.8 vs 3.2 ± 0.7 ug/ml (P = 0. 08). Conclusions: Treatment with liraglutide, and/or associated weight loss, significantly reduced PIIINP levels in obese women with PCOS. This may be an additional beneficial factor when considering the use of liraglutide in women with PCOS, obesity and NAFLD.

AB - Introduction: Nonalcoholic fatty liver disease (NAFLD) has been linked to polycystic ovary syndrome (PCOS) and carries an increased risk of liver cirrhosis. Procollagen type 3 amino-terminal peptide (PIIINP) is an independent predictor of liver cirrhosis. Objective: To assess whether 6-month treatment with GLP-1 analogue, liraglutide, improves markers of liver fibrosis. Design: A case-control study comparing women with PCOS to age- and weight-matched controls. PCOS was diagnosed according to the Rotterdam criteria. All participants underwent liver function tests and liver ultrasound scan to assess for fatty infiltration. Serum marker for liver fibrosis, PIIINP, was measured at baseline and after 6-month treatment with liraglutide 1.8 mg od. Results: Nineteen women with PCOS and 17 controls were recruited, age 32.8 ± 7.2 vs 33.5 ± 6.7 years and weight 100.9 ± 16.7 vs 99.3 ± 14.7 kg, respectively. At baseline, the PCOS group had higher testosterone 1.2 ± 0.3 vs 0.9 ± 0.3 nM (P = 0.01), HOMA-IR 5.1 ± 2.6 vs 3.5 ± 1.3 (P = 0.03), AST 22.4 ± 5.2 vs 18.8 ± 3.4 u/l (P = 0.04), PIIINP 4.4 ± 0.8 vs 3.5 ± 0.8 ug/ml (P = 0.01) and NAFLD seven (35%) vs none (P = 0.005), respectively. Twenty-five (69%) participants completed the study (13 PCOS, 12 controls). Following treatment, weight was reduced by 3.0 ± 4.2 kg (P = 0.01) and 3.8 ± 3.4 kg (P = 0.001), respectively. Similarly, HOMA-IR, hsCRP, triglycerides and urinary isoprostane significantly reduced in both groups. PIIINP significantly reduced the in PCOS group 4.4 ± 0.8 vs 3.7 ± 0.9 ug/ml (P < 0.01), but not in controls 3.5 ± 0.8 vs 3.2 ± 0.7 ug/ml (P = 0. 08). Conclusions: Treatment with liraglutide, and/or associated weight loss, significantly reduced PIIINP levels in obese women with PCOS. This may be an additional beneficial factor when considering the use of liraglutide in women with PCOS, obesity and NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=84908097545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908097545&partnerID=8YFLogxK

U2 - 10.1111/cen.12369

DO - 10.1111/cen.12369

M3 - Article

VL - 81

SP - 523

EP - 528

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 4

ER -